The COVID-19 (COVID-19) Current Therapy by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).
Learn More On The COVID-19 (COVID-19) Current Therapy Market:
https://www.thebusinessresearchcompany.com/report/coronavirus-current-therapy-global-market-report
According to The Business Research Company’s COVID-19 (COVID-19) Current Therapy, The coronavirus (covid-19) current therapy market size has declined steeply in recent years. It will decline from $11.73 billion in 2023 to $5.87 billion in 2024 at a compound annual growth rate (CAGR) of -50.0%. The decline in the historic period can be attributed to limited treatment options, varying treatment efficacy, supply chain disruptions, rapidly evolving scientific knowledge, emergence of variants.
The coronavirus (covid-19) current therapy market size is expected to see steep decline in the next few years. It will decline to $2.34 billion in 2025 at a compound annual growth rate (CAGR) of -60.1%. The decline in the forecast period can be attributed to global vaccine rollout impact, long-term effects and chronic cases, regulatory and market access challenges, global economic factors. Major trends in the forecast period include investing in developing monoclonal antibody therapies, convalescent plasma therapies, cell-based therapies, and antiviral therapies, collaboration with government institutions and undergoing strategic partnerships with other pharmaceutical companies.
The outbreak of the pandemic COVID-19 contributed to the growth of the coronavirus (COVID-19) current therapy market. The World Health Organization (WHO) declared the outbreak a global pandemic. For instance, in August 2022, according to the World Health Organization, a Switzerland-based specialized agency of the United Nations, the global COVID-19 cases reached 581.8 million. As there is no officially approved drug for COVID-19, the demand has risen significantly for repurposed drugs that are used for corona therapy. Countries across the world are facing shortages of drugs, and drug manufacturers are ramping up production to meet the global demand. The Coronavirus Treatment Acceleration Program (CTAP) is a special emergency program initiated by the FDA for the development of potential COVID-19 therapies to be made available to patients as quickly as possible.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=3247&type=smp
The coronavirus (covid-19) current therapy market covered in this report is segmented –
1) By Drug Type: Antiviral, Monoclonal Antibodies, Corticosteroid, Supplements, Antimalarial, Interferons And Interleukin Inhibitors, Other Anti-Infective Drugs, Others
1) By Route Of Administration: Oral, Intravenous
2) By End-User: Hospitals, Clinics, Home Care, Others
Convalescent Plasma Therapy is used as an experimental therapy to treat COVID-19 patients. The blood plasma of patients who have recovered from a disease is called convalescent plasma (CP). Convalescent plasma therapy (CP) is a type of passive antibody therapy in which blood plasma is isolated from patients who have recovered from the disease of interest and administered to a patient with severe disease in order to suppress virulence and improve clinical symptoms. The blood plasma of recovered COVID-19 patients has antibodies to fight COVID-19 infection. According to guidance issued by the FDA, Convalescent Plasma Therapy is recommended as an investigational product during a public health emergency. Around 2,004 participating sites adhering to a single expanded access protocol by the US FDA had been registered, around 7,774 patients had enrolled, and 3,809 of them had undergone convalescent plasma transfusion. The experimental convalescent plasma therapy is likely to gain attention if enough data is supports the results.
The covid-19 (covid-19) current therapy market report table of contents includes:
1. Executive Summary
2. COVID-19 (COVID-19) Current Therapy Market Market Characteristics
3. COVID-19 (COVID-19) Current Therapy Market Market Trends And Strategies
4. COVID-19 (COVID-19) Current Therapy Market Market Size And Growth
5. COVID-19 (COVID-19) Current Therapy Market Segmentation.
…..
7. COVID-19 (COVID-19) Current Therapy Market Regional And Country Analysis
27 COVID-19 (COVID-19) Current Therapy Market Competitive Landscape And Company Profiles
28. COVID-19 (COVID-19) Current Therapy Market Key Mergers And Acquisitions
29. COVID-19 (COVID-19) Current Therapy Market Future Outlook and Potential Analysis
30. Appendix
Related Reports:
https://topprnews.com/seaweed-cultivation-marke-trends/
https://topprnews.com/security-as-a-service-market-forecast/
https://topprnews.com/security-orchestration-automation-and-response-soar-market-forecast/
https://goodprnews.com/dental-flap-surgery-market-trends/
https://goodprnews.com/depyrogenated-sterile-empty-vials-market-forecast/
https://goodprnews.com/desktop-virtualization-market-trends/
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
